Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: A multi-stage, randomised, double-blind, placebo-controlled trial.
The Lancet Neurology.
Times cited: 64
- Reply from the authors. Neurology. 2009 Article GET IT
Subcutaneous IGF-1 is not beneficial in 2-year ALS trial.
Times cited: 167